contact us
The FDA approves Melinta Therapeutics' (NASDAQ:MLNT) BAXDELA (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP).
Do Not Allow Advertisers to Use My Personal information